FibroGen Inc (NASDAQ:FGEN) – Stock analysts at Svb Leerink upped their FY2019 EPS estimates for FibroGen in a report released on Tuesday, November 12th. Svb Leerink analyst G. Porges now anticipates that the biopharmaceutical company will earn ($0.06) per share for the year, up from their previous estimate of ($0.69). Svb Leerink also issued estimates for FibroGen’s Q4 2019 earnings at ($0.30) EPS, Q1 2020 earnings at ($0.73) EPS, Q2 2020 earnings at $3.41 EPS and Q4 2020 earnings at ($0.70) EPS.
FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.02. FibroGen had a return on equity of 7.50% and a net margin of 11.81%. The firm had revenue of $33.17 million for the quarter, compared to the consensus estimate of $31.61 million. During the same quarter in the previous year, the business earned ($0.50) EPS. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis.
A number of other analysts also recently commented on the company. TheStreet raised FibroGen from a “d+” rating to a “c” rating in a research note on Tuesday, August 13th. Mizuho reissued a “positive” rating and issued a $72.00 price objective (up previously from $65.00) on shares of FibroGen in a research note on Monday. BidaskClub raised FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, October 17th. ValuEngine raised FibroGen from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. Finally, Zacks Investment Research downgraded FibroGen from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $58.33.
Shares of FGEN traded up $1.66 during midday trading on Friday, reaching $36.64. The stock had a trading volume of 14,307 shares, compared to its average volume of 1,108,981. FibroGen has a 52 week low of $32.33 and a 52 week high of $61.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.73 and a quick ratio of 9.71. The firm’s 50 day moving average price is $38.34 and its 200-day moving average price is $41.69. The company has a market capitalization of $3.09 billion, a P/E ratio of -35.48 and a beta of 1.84.
In other news, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the sale, the chief executive officer now directly owns 2,356,578 shares of the company’s stock, valued at $104,467,102.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Pat Cotroneo sold 3,201 shares of FibroGen stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $41.38, for a total value of $132,457.38. Following the transaction, the chief financial officer now owns 244,432 shares in the company, valued at approximately $10,114,596.16. The disclosure for this sale can be found here. Insiders have sold 86,756 shares of company stock worth $3,644,083 over the last ninety days. 8.96% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of FGEN. Captrust Financial Advisors acquired a new stake in shares of FibroGen in the 2nd quarter worth about $90,000. US Bancorp DE grew its stake in shares of FibroGen by 79.7% in the second quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 963 shares during the last quarter. Usca Ria LLC bought a new stake in shares of FibroGen in the third quarter worth $123,000. Convergence Investment Partners LLC bought a new stake in shares of FibroGen in the third quarter worth $137,000. Finally, Nisa Investment Advisors LLC grew its stake in shares of FibroGen by 729.8% in the third quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 3,430 shares during the last quarter. Institutional investors and hedge funds own 69.03% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Story: Market Capitalization
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.